Context Therapeutics Q3 net loss $7.6M; CTIM-76 shows 22% ORR in PROC at weekly doses

Context Therapeutics Inc.

2026-Q3 EPS reported -$0.32

Q3 2026 net loss $7.6M vs $9.7M in Q3 2025; R&D $5.7M vs $8.7M, G&A $2.2M vs $1.9M.
Cash and equivalents $34.4M at Sept 30, 2026, down from $66.0M at Dec 31, 2025; runway expected into early Q4 2027.
CTIM-76 in 9 efficacy-evaluable PROC patients at 140–280 µg weekly: 22% confirmed ORR, 56% DCR, median PFS 5.6 months.
Safety: CRS in 5 of 27 patients (18.5%), all Grade 1/2; Grade ≥3 TEAEs in 81.5%, with dose-related Grade ≥3 liver enzyme elevations.
DLT period at 280 µg every three weeks complete; escalation to 420 µg Q3W begun; Phase 1b initiation expected Q1 2027, initial Q3W efficacy data Q2 2027.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.